PAP
TVTX icon

Persistent Asset Partners’s Travere Therapeutics TVTX Stock Holding History

Persistent Asset Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,291
Closed -$126K – 474
2025
Q4 		$126K Buy
+3,291
New +$107K 0.06% 254

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Persistent Asset Partners's TVTX Position: Q1 2026 in Review

Persistent Asset Partners sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 3,291 shares — an estimated $126K sold.

Persistent Asset Partners first reported a position in TVTX in Q4 2025 and held it in 1 quarter. The position peaked at $126K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Persistent Asset Partners reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 3,291 Travere Therapeutics shares in Q1 2026, an estimated $126K.
  • Persistent Asset Partners first reported a position in Travere Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Travere Therapeutics position peaked at $126K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.